Sarcopenia Treatment Market by Treatment (Protein Supplements, Vitamin B12 Supplements, Vitamin D & Calcium Supplements and Others), Route of Administration (Oral, Parenteral, and Enteral), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies: Global Opportunity Analysis and Industry -Forecast up to 2027
The sarcopenia treatment market refers to the industry that focuses on the development, production, and distribution of therapies and interventions for the treatment of sarcopenia. Sarcopenia is a condition characterized by the loss of muscle mass, strength, and function that occurs with aging. It is a significant contributor to frailty, disability, and reduced quality of life in older adults. The sarcopenia treatment market is likely to grow at a rate of 6.3% CAGR by 2027.
The Sarcopenia Treatment Market on the basis of Treatment
Protein Supplements
Vitamin B12 Supplements
Vitamin D & Calcium Supplements
The Sarcopenia Treatment Market on the basis of Route of Administration
Oral
Parenteral
Enteral
The Sarcopenia Treatment Market on the basis of Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies
The Sarcopenia Treatment Market on the basis of Geography
North America
Europe
Asia Pacific
Rest of the World
Market Size and Growth:
The sarcopenia treatment market has gained attention and is expected to grow significantly in response to the aging population and the increasing recognition of sarcopenia as a significant public health issue. The market's growth is driven by the need for effective interventions to prevent, manage, and treat sarcopenia. In addition to this, the
Therapeutic Approaches:
Exercise and Physical Therapy: Regular exercise, including resistance training and aerobic activities, is considered a cornerstone in the management and treatment of sarcopenia. Physical therapy interventions may also be employed to improve muscle strength, mobility, and function.
Nutritional Interventions: Adequate nutrition, including protein intake and appropriate caloric balance, plays a vital role in the prevention and treatment of sarcopenia. Nutritional interventions may involve dietary modifications and the use of specific supplements or medical nutrition products.
Pharmacological Therapies: Various drugs and pharmacological interventions are being investigated for their potential to counteract muscle loss and improve muscle function in sarcopenia. These include anabolic agents, selective androgen receptor modulators (SARMs), myostatin inhibitors, and other novel drug candidates.
Multimodal Approaches: Combining multiple interventions, such as exercise, nutrition, and pharmacological therapies, is often recommended to achieve synergistic effects in the management of sarcopenia.
Market Drivers:
Increasing Aging Population: The global population is experiencing a significant increase in the number of elderly individuals. Sarcopenia, which is the age-related loss of muscle mass and function, is a common condition among older adults. The rising aging population directly fuels the demand for effective sarcopenia treatments which drives market growth.
Growing Awareness: Increased awareness among healthcare professionals and the general population about the impact of sarcopenia on health and quality of life is further driving the demand for treatment options.
Research and Innovation: Ongoing research efforts and advancements in understanding the underlying mechanisms of sarcopenia are fueling the development of new therapeutic approaches and interventions.
Health and Wellness Industry: The emphasis on healthy aging, preventive healthcare, and active lifestyles has led to a greater focus on addressing age-related muscle loss and promoting muscle health. Thus, the emphasis on health and wellness is driving the demand for sarcopenia treatments.
Challenges:
Diagnostic Challenges: Sarcopenia diagnosis is complex, involving the assessment of muscle mass, strength, and physical performance. Consensus on standardized diagnostic criteria and tools is still evolving, which may pose challenges in identifying and enrolling patients for clinical trials and treatment.
Regulatory Considerations: The regulatory pathway for approving treatments specifically targeting sarcopenia is still evolving, and there may be challenges related to clinical trial design and regulatory approval.
Multifactorial Nature: Sarcopenia is a multifactorial condition influenced by various factors, including genetics, lifestyle, comorbidities, and nutrition. Designing interventions that effectively target these factors and their interactions can be challenging.
The leading players of the Sarcopenia treatment market are Abbott laboratories, Inc., American Way (Amway) Corporation, Bayer AG, GlaxoSmithKlineplc., Nestle S.A., Pfizer, Inc., Novartis AG, Sanofi, Inc., Zydus Cadila, Ltd, and F-Hoffmann La-Roche
The report analyzes the geographical highlights in terms of consumption of the product/service within the region also indicates the factors which are affecting the market within each region.
The report consists of opportunities and challenges faced by the players in the global non-small cell lung cancer
The report implies the regional and segmental analysis which is projected to witness the fastest growth.
Provides competitive outlook which includes the market ranking of the key players, coupled with new product launches, partnerships, business expansions, and acquisitions.
The Sarcopenia Treatment Market on the basis of Treatment
Protein Supplements
Vitamin B12 Supplements
Vitamin D & Calcium Supplements
The Sarcopenia Treatment Market on the basis of Route of Administration
Oral
Parenteral
Enteral
The Sarcopenia Treatment Market on the basis of Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies
The Sarcopenia Treatment Market on the basis of Geography
North America
Europe
Asia Pacific
Rest of the World
Market Size and Growth:
The sarcopenia treatment market has gained attention and is expected to grow significantly in response to the aging population and the increasing recognition of sarcopenia as a significant public health issue. The market's growth is driven by the need for effective interventions to prevent, manage, and treat sarcopenia. In addition to this, the
Therapeutic Approaches:
Exercise and Physical Therapy: Regular exercise, including resistance training and aerobic activities, is considered a cornerstone in the management and treatment of sarcopenia. Physical therapy interventions may also be employed to improve muscle strength, mobility, and function.
Nutritional Interventions: Adequate nutrition, including protein intake and appropriate caloric balance, plays a vital role in the prevention and treatment of sarcopenia. Nutritional interventions may involve dietary modifications and the use of specific supplements or medical nutrition products.
Pharmacological Therapies: Various drugs and pharmacological interventions are being investigated for their potential to counteract muscle loss and improve muscle function in sarcopenia. These include anabolic agents, selective androgen receptor modulators (SARMs), myostatin inhibitors, and other novel drug candidates.
Multimodal Approaches: Combining multiple interventions, such as exercise, nutrition, and pharmacological therapies, is often recommended to achieve synergistic effects in the management of sarcopenia.
Market Drivers:
Increasing Aging Population: The global population is experiencing a significant increase in the number of elderly individuals. Sarcopenia, which is the age-related loss of muscle mass and function, is a common condition among older adults. The rising aging population directly fuels the demand for effective sarcopenia treatments which drives market growth.
Growing Awareness: Increased awareness among healthcare professionals and the general population about the impact of sarcopenia on health and quality of life is further driving the demand for treatment options.
Research and Innovation: Ongoing research efforts and advancements in understanding the underlying mechanisms of sarcopenia are fueling the development of new therapeutic approaches and interventions.
Health and Wellness Industry: The emphasis on healthy aging, preventive healthcare, and active lifestyles has led to a greater focus on addressing age-related muscle loss and promoting muscle health. Thus, the emphasis on health and wellness is driving the demand for sarcopenia treatments.
Challenges:
Diagnostic Challenges: Sarcopenia diagnosis is complex, involving the assessment of muscle mass, strength, and physical performance. Consensus on standardized diagnostic criteria and tools is still evolving, which may pose challenges in identifying and enrolling patients for clinical trials and treatment.
Regulatory Considerations: The regulatory pathway for approving treatments specifically targeting sarcopenia is still evolving, and there may be challenges related to clinical trial design and regulatory approval.
Multifactorial Nature: Sarcopenia is a multifactorial condition influenced by various factors, including genetics, lifestyle, comorbidities, and nutrition. Designing interventions that effectively target these factors and their interactions can be challenging.
The leading players of the Sarcopenia treatment market are Abbott laboratories, Inc., American Way (Amway) Corporation, Bayer AG, GlaxoSmithKlineplc., Nestle S.A., Pfizer, Inc., Novartis AG, Sanofi, Inc., Zydus Cadila, Ltd, and F-Hoffmann La-Roche
The report analyzes the geographical highlights in terms of consumption of the product/service within the region also indicates the factors which are affecting the market within each region.
The report consists of opportunities and challenges faced by the players in the global non-small cell lung cancer
The report implies the regional and segmental analysis which is projected to witness the fastest growth.
Provides competitive outlook which includes the market ranking of the key players, coupled with new product launches, partnerships, business expansions, and acquisitions.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TREATMENT: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Protein Supplements
5.3. Vitamin B12 Supplements
5.4. Vitamin D & Calcium Supplements
6. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Oral
6.3. Parenteral
6.4. Enteral
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospital Pharmacies
7.3. Drug Stores & Retail Pharmacies
7.4. Online Pharmacies
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. Abbott laboratories, Inc.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. American Way (Amway) Corporation
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Bayer AG
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. GlaxoSmithKline plc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Nestle S.A.
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Pfizer, Inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Novartis AG
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Sanofi, Inc.
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Zydus Cadila, Ltd
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. F-Hoffmann La-Roche
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TREATMENT: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Protein Supplements
5.3. Vitamin B12 Supplements
5.4. Vitamin D & Calcium Supplements
6. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Oral
6.3. Parenteral
6.4. Enteral
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospital Pharmacies
7.3. Drug Stores & Retail Pharmacies
7.4. Online Pharmacies
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. Abbott laboratories, Inc.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. American Way (Amway) Corporation
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Bayer AG
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. GlaxoSmithKline plc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Nestle S.A.
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Pfizer, Inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Novartis AG
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Sanofi, Inc.
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Zydus Cadila, Ltd
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. F-Hoffmann La-Roche
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR PROTEIN SUPPLEMENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR VITAMIN B12 SUPPLEMENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR VITAMIN D & CALCIUM SUPPLEMENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR PARENTERAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR ENTERAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR DRUG STORES & RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR ONLINE PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA SARCOPENIA TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 17. NORTH AMERICA SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 18. U.S SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 19. U.S SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 20. U.S SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. CANADA SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 22. CANADA SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 23. CANADA SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 24. EUROPE SARCOPENIA TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 25. EUROPE SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 26. EUROPE SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 27. EUROPE SARCOPENIA TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 28. GERMANY SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 29. GERMANY SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 30. GERMANY SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 31. U.K SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 32. U.K SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 33. U.K SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. FRANCE SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 35. FRANCE SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 36. FRANCE SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 37. ITALY SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 38. ITALY SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 39. ITALY SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. SPAIN SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 41. SPAIN SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 42. SPAIN SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 43. ROE SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 44. ROE SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 45. ROE SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC SARCOPENIA TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 49. ASIA PACIFC SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 50. CHINA SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 51. CHINA SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 52. CHINA SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 53. INDIA SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 54. INDIA SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 55. INDIA SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 56. JAPAN SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 57. JAPAN SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 58. JAPAN SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 61. REST OF APAC SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 64. REST OF WORLD SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 65. ABBOTT LABORATORIES, INC.: FINANCIALS
TABLE 66. ABBOTT LABORATORIES, INC.: PRODUCTS & SERVICES
TABLE 67. ABBOTT LABORATORIES, INC.: RECENT DEVELOPMENTS
TABLE 68. AMERICAN WAY (AMWAY) CORPORATION: FINANCIALS
TABLE 69. AMERICAN WAY (AMWAY) CORPORATION: PRODUCTS & SERVICES
TABLE 70. AMERICAN WAY (AMWAY) CORPORATION: RECENT DEVELOPMENTS
TABLE 71. BAYER AG: FINANCIALS
TABLE 72. BAYER AG: PRODUCTS & SERVICES
TABLE 73. BAYER AG: RECENT DEVELOPMENTS
TABLE 74. GLAXOSMITHKLINE PLC.: FINANCIALS
TABLE 75. GLAXOSMITHKLINE PLC.: PRODUCTS & SERVICES
TABLE 76. GLAXOSMITHKLINE PLC.: RECENT DEVELOPMENTS
TABLE 77. NESTLE S.A.: FINANCIALS
TABLE 78. NESTLE S.A.: PRODUCTS & SERVICES
TABLE 79. NESTLE S.A.: RECENT DEVELOPMENTS
TABLE 80. PFIZER, INC.: FINANCIALS
TABLE 81. PFIZER, INC.: PRODUCTS & SERVICES
TABLE 82. PFIZER, INC.: RECENT DEVELOPMENTS
TABLE 83. NOVARTIS AG: FINANCIALS
TABLE 84. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 85. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 86. SANOFI, INC.: FINANCIALS
TABLE 87. SANOFI, INC.: PRODUCTS & SERVICES
TABLE 88. SANOFI, INC.: RECENT DEVELOPMENTS
TABLE 89. ZYDUS CADILA, LTD: FINANCIALS
TABLE 90. ZYDUS CADILA, LTD: PRODUCTS & SERVICES
TABLE 91. ZYDUS CADILA, LTD: RECENT DEVELOPMENTS
TABLE 92. F-HOFFMANN LA-ROCHE: FINANCIALS
TABLE 93. F-HOFFMANN LA-ROCHE: PRODUCTS & SERVICES
TABLE 94. F-HOFFMANN LA-ROCHE: RECENT DEVELOPMENTS
TABLE 1. GLOBAL SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR PROTEIN SUPPLEMENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR VITAMIN B12 SUPPLEMENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR VITAMIN D & CALCIUM SUPPLEMENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR PARENTERAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR ENTERAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR DRUG STORES & RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. GLOBAL SARCOPENIA TREATMENT MARKET VALUE FOR ONLINE PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA SARCOPENIA TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 17. NORTH AMERICA SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 18. U.S SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 19. U.S SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 20. U.S SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. CANADA SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 22. CANADA SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 23. CANADA SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 24. EUROPE SARCOPENIA TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 25. EUROPE SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 26. EUROPE SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 27. EUROPE SARCOPENIA TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 28. GERMANY SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 29. GERMANY SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 30. GERMANY SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 31. U.K SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 32. U.K SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 33. U.K SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. FRANCE SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 35. FRANCE SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 36. FRANCE SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 37. ITALY SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 38. ITALY SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 39. ITALY SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. SPAIN SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 41. SPAIN SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 42. SPAIN SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 43. ROE SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 44. ROE SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 45. ROE SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC SARCOPENIA TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 49. ASIA PACIFC SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 50. CHINA SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 51. CHINA SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 52. CHINA SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 53. INDIA SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 54. INDIA SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 55. INDIA SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 56. JAPAN SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 57. JAPAN SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 58. JAPAN SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 61. REST OF APAC SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD SARCOPENIA TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD SARCOPENIA TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 64. REST OF WORLD SARCOPENIA TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 65. ABBOTT LABORATORIES, INC.: FINANCIALS
TABLE 66. ABBOTT LABORATORIES, INC.: PRODUCTS & SERVICES
TABLE 67. ABBOTT LABORATORIES, INC.: RECENT DEVELOPMENTS
TABLE 68. AMERICAN WAY (AMWAY) CORPORATION: FINANCIALS
TABLE 69. AMERICAN WAY (AMWAY) CORPORATION: PRODUCTS & SERVICES
TABLE 70. AMERICAN WAY (AMWAY) CORPORATION: RECENT DEVELOPMENTS
TABLE 71. BAYER AG: FINANCIALS
TABLE 72. BAYER AG: PRODUCTS & SERVICES
TABLE 73. BAYER AG: RECENT DEVELOPMENTS
TABLE 74. GLAXOSMITHKLINE PLC.: FINANCIALS
TABLE 75. GLAXOSMITHKLINE PLC.: PRODUCTS & SERVICES
TABLE 76. GLAXOSMITHKLINE PLC.: RECENT DEVELOPMENTS
TABLE 77. NESTLE S.A.: FINANCIALS
TABLE 78. NESTLE S.A.: PRODUCTS & SERVICES
TABLE 79. NESTLE S.A.: RECENT DEVELOPMENTS
TABLE 80. PFIZER, INC.: FINANCIALS
TABLE 81. PFIZER, INC.: PRODUCTS & SERVICES
TABLE 82. PFIZER, INC.: RECENT DEVELOPMENTS
TABLE 83. NOVARTIS AG: FINANCIALS
TABLE 84. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 85. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 86. SANOFI, INC.: FINANCIALS
TABLE 87. SANOFI, INC.: PRODUCTS & SERVICES
TABLE 88. SANOFI, INC.: RECENT DEVELOPMENTS
TABLE 89. ZYDUS CADILA, LTD: FINANCIALS
TABLE 90. ZYDUS CADILA, LTD: PRODUCTS & SERVICES
TABLE 91. ZYDUS CADILA, LTD: RECENT DEVELOPMENTS
TABLE 92. F-HOFFMANN LA-ROCHE: FINANCIALS
TABLE 93. F-HOFFMANN LA-ROCHE: PRODUCTS & SERVICES
TABLE 94. F-HOFFMANN LA-ROCHE: RECENT DEVELOPMENTS
